MaxCyte Share News (MXCT)

MaxCyte Information

Buy MXCT Shares
Add MXCT to Watchlist
Add MXCT to Alert

Share Price Information for MaxCyte (MXCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 345.00

Bid: 340.00

Ask: 350.00

Change: -12.00 (-3.36%)

Spread: 10.00 (2.941%)

Open: 355.00

High: 355.00

Low: 345.00

Prev. Close: 357.00

Last checked at -

IN BRIEF: MaxCyte prepares for listing in New York

Fri, 14th May 2021 14:13

MaxCyte Inc - platform technologies provider for cell engineering - Submits a draft registration statement with the Securities & Exchange Commission relating to a proposed dual-listing and public offering on the Nasdaq Stock Market in New York. The company says the number of securities to be offered and their price has not yet been determined. The offering is expected to start after the comission completes its review process.

Current stock price: 902.50 pence, up 0.3% on Friday

Year-to-date change: up 71%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

More News

9 Apr 2020 14:54

UK TRADING UPDATE SUMMARY: Naked Wines, Distil Get Bar-Closure Boost

21 Feb 2020 11:53

MaxCyte to consolidate stock to single trading line

(Sharecast News) - Life sciences company MaxCyte announced the consolidation of its two lines of common stock into a single unrestricted line of common stock on Friday.

20 Jan 2020 10:58

MaxCyte 'exceptionally positive' following strong FY trading performance

(Sharecast News) - Clinical-stage life sciences company MaxCyte told investors on Monday that its board was "exceptionally positive" of the group's future following a stellar year.

20 Jan 2020 09:00

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

4 Dec 2019 16:14

MaxCyte inks new development agreement with KSQ Therapeutics

(Sharecast News) - Cell-based therapeutics and life sciences company MaxCyte has entered into a new development and commercialisation agreement with its existing partner KSQ Therapeutics, it announced on Wednesday.

4 Dec 2019 11:50

MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics

21 Nov 2019 18:55

MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma

21 Nov 2019 16:40

MaxCyte strikes deal with oncology company Vor Biopharma

(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licence agreement with oncology company Vor Biopharma on Thursday, under which Vor would use MaxCyte's 'Flow Electroporation' technology to produce engineered hematopoietic stem cells (eHSCs), and initiate investigational new drug-enabling studies to accelerate its progress towards the clinic.

24 Oct 2019 12:53

MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11

7 Oct 2019 12:23

MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included

18 Sep 2019 11:59

MaxCyte Interim Rises Revenue But Loss Widens On CARMA Investment

(Alliance News) - Life sciences company MaxCyte Inc on Wednesday reported first half revenue growth but its loss widened as expenses soared.In the six months to June 30, the firm's rose

11 Sep 2019 16:04

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 12 September WM Morrison SupermarketsHalf Year ResultsBrooks MacdonaldFull Year

17 Jul 2019 13:43

MaxCyte Progresses On MCY-M11 Development As Interim Revenue Rises

(Alliance News) - MaxCyte Inc on Wednesday reported double-digit revenue growth in the first half of 2019 and expects to see continued progress throughout the second half of the year.The is

26 May 2019 21:53

Sunday share tips: IQE, MaxCyte

(Sharecast News) - In his 'Inside the City' column for The Sunday Times, Ben Woods looked at the effect of Donald Trump's posturing against Huawei on the chipmaking industry - particularly, wafer semiconductor technology minnow IQE.

8 May 2019 15:58

MaxCyte begins dosing second cohort in MCY-M11 clinical trial

(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.

Latest Share Chat

MaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: MaxCyte prepares for listing in New York

Login to your account

Quickpicks are a member only feature

Login to your account